NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

癌症生物毒性藥物的全球市場:機會/治療藥物銷售和臨床試驗(∼2026)

Global Cancer Biological Toxins Drug Market Opportunity, Drug Sales & Clinical Trials Insight 2026

出版商 KuicK Research 商品編碼 985629
出版日期 內容資訊 英文 330 Pages
商品交期: 最快1-2個工作天內
價格
癌症生物毒性藥物的全球市場:機會/治療藥物銷售和臨床試驗(∼2026) Global Cancer Biological Toxins Drug Market Opportunity, Drug Sales & Clinical Trials Insight 2026
出版日期: 2021年02月02日內容資訊: 英文 330 Pages
簡介

用於癌症的生物毒性藥物具有廣闊的整體市場前景,其廣泛的應用將改變未來的癌症治療前景並實現可持續的結果。

市場的主要推動力是癌症病例的增加,癌症死亡率的增加,對生物毒素在癌症中應用的認識的提高以及市場上可獲得的其他較高的治療方法,例如失敗率。

本報告調查並分析了癌症生物毒性藥物的全球市場,概述了市場,生物毒素在癌症管理中的作用,靶向癌症的生物毒素的類型以及癌症的生物毒素,並分析了市場增長對其他藥物的影響。癌症治療,各種癌症的生物毒素,研究趨勢,臨床研究和主要公司。

目錄

第1章生物毒物簡介

  • 概述
  • 生物毒素作為強大的抗癌藥的發展

第2章生物毒素在癌症管理中的作用

第3章針對癌症的生物毒物的類型

  • 正鏈RNA
  • 毛孔形成毒素
  • 炭疽毒素

第4章癌症生物毒性市場的增長對其他可行的癌症治療方法的影響

  • 癌症生物毒素市場對全球癌症免疫療法市場的影響
    • 癌症的生物毒性藥物與免疫檢查點抑製劑治療
    • 癌症生物毒性藥物與免疫療法單克隆抗體的比較
    • 用於癌症的生物毒性藥物與癌症疫苗市場的比較
  • 全球癌症生物毒性治療市場對過去和傳統癌症治療的影響
    • 癌症的生物毒性藥物與癌症患者的化學療法
    • 用於癌症的生物毒性藥物與用於癌症治療的放射治療
    • 癌症的生物毒性藥物與癌症治療的外科手術

第5章腦腫瘤的生物毒物

  • 用於靶向腦腫瘤的毒素
  • 銅綠假單胞菌基於外毒素的腦腫瘤免疫毒素
    • IL4-PE
    • IL13-PE
    • TP-38
  • 基於白喉毒素的腦腫瘤免疫毒素
    • Tf-CRM107
    • DTAT和DTAT13
  • 靶向腦腫瘤的抗原
    • 轉鐵蛋白受體
    • 白介素4受體
    • 白介素13受體
    • 表皮生長因子受體
    • 其他抗原

第6章血液腫瘤的生物毒物

  • 生物毒素在白血病和淋巴瘤中的作用
  • 正在進行的研發

第7章用於靶向實體瘤的生物毒物

  • 對實體瘤治療的影響
  • 正在進行的研究與進展

第8章乳腺癌的生物毒物

  • 生物毒素在乳腺癌中的應用
  • 持續發展

第9章肺癌的生物毒性

  • 角色和應用程序
  • 最新研發

第10章其他癌症的生物毒物

  • 前列腺癌
  • 黑色素瘤
  • 大腸癌
  • 婦科癌症
  • 胃腸道癌

第11章全球免疫毒素市場:可用性,劑量,專利和價格分析

  • Lumoxiti(Moxetumomab pasudotox)

第12章癌症生物毒素市場的研究與醫學進展

  • UCLA研究人員使用來自Diazona angulata(海鮮)的蛋白質來最大程度地減少癌症副作用
  • 肉毒桿菌毒素對患者的胃癌細胞有效
  • 肉毒桿菌毒素A大大減少了食道癌治療後的併發症
  • 肉毒桿菌毒素A治療皮膚平滑肌瘤效果更好
  • TR1801-ADC用於治療晚期實體瘤的特徵
  • 肉毒桿菌毒素增強化學療法和放射療法的有效性
  • 肉毒桿菌毒素A治療乳腺癌手術後的持續疼痛
  • 新發現的肉毒桿菌毒素X可能有助於治療癌症和其他疾病

第13章癌症的生物毒素:臨床試驗見解

  • 按階段
  • 按狀態
  • 按癌症類型
  • 按國家

第14章:全球癌症生物毒素的臨床研究:按公司,適應症和階段劃分

  • 研究
  • 臨床前
  • 第一階段
  • 一期/二期
  • 第二階段
  • II/III期
  • 第三階段
  • 預註冊
  • 已註冊

第15章關於非處方癌症生物毒素的臨床見解:莫西酮單抗Pasudotox(Lumoxiti)

第16章癌症生物毒性藥物的全球市場動態

  • 有利的市場參數
  • 市場挑戰

第17章癌症生物毒性市場的未來方向

第18章競爭情況

  • Angimmune
  • Eisai
  • Molecular Template (mTEM)
  • Astrazeneca
  • Research Corporation Technologies
  • Sanofi
  • Seattle Genetics
  • Roche
  • Neopharma
  • Xenova Biomedix
目錄

"Global Cancer Biological Toxins Drug Market Opportunity, Drug Sales & Clinical Trials Insight 2026" Report Highlights:

  • Cancer Biological Toxins Clinical Trials: >70 Drugs in Pipeline
  • Global Cancer Biological Toxins Expected Market Opportunity: > US$ 200 Million
  • Biological Toxins Drug Insight by Cancer
  • Cancer Biological Toxins Clinical Trial Insight by Phase, Status, Cancer & Country
  • Marketed Cancer Biological Toxin Clinical Insight: Moxetumomab Pasudotox (Lumoxiti)

The fast pace of cancer prevalence and mortality rate across the globe has led to an increasing concern as well as recognition that the specific disease requires attention by the researchers. In the past few years, the type of research activities that have been conducted for cancer disease has moved several laboratory findings to the commercial world. In one of the scenarios, development of cancer biological toxins is a form of novel technology facility resulted from the translational research conducted at different research centers. The therapy developed and re-defined by hundreds of researchers in the past few years is witnessed to facilitate promising cancer targets in its preclinical as well as clinical research. The comprehensive outlook for the market appears to the positive, in terms of sustainable results achieved and its wide range applications to alter the future cancer therapeutics landscape.

While hundreds of other cancer therapies are failing to stake their applications in treating cancer patients, cancer biological toxin therapy is caught in the middle to get recognized as an offering that is unimaginable. The market since its emergence has remained ahead with respect to the overall survival rate it is delivering as well as solving the entire healthcare problems related with cancer development and progression. Several drug makers in today's world are getting involved in boosting the value chain of the market by delivering conventional thinking and re-defining the entire role of their research and development sector for the market expansion.

The market since its arrival in the cancer therapeutics market at global level has remained successful in reconfiguring today's cancer challenges by causing a shift from only being a therapy to becoming one of the standard healthcare regimens for millions of patients. All this is inclining the market towards poised growth, where in the next few years, the market will observe an influx in the market size by huge percentage. The several highlights of the market are also projecting increase in demand of the drug products available under it as the disease lifestyle is becoming more prevalent, thus making the researchers unlock more hidden potential of the therapy for different cancer patient types.

Traditionally, the cancer biological toxin market is prone to deliver and provide value in terms of complete eradication of the cancer cells by performing splendid research and development activities. But an important reason that has led to substantial rise in the clinical and research activities related with cancer is the overhaul that the other available cancer therapies had created for the past many decades. This resulted in the foundational shift in the entire cancer therapeutics industry and thus, the emergence of therapy that involves toxins isolated from prokaryotes for killing the cancer cells. To date, researchers have been successful in isolating and studying the expression of biological toxins from different organisms for killing cancer cells but one most studied bacterium for the therapy is Clostridium botulinum.

The respective bacterium and several others have promised highest returns for the cancer patients. Also, the toxins isolated from such living organisms and their transformation into drug products have led to the representation of the therapy in top best-selling cancer therapies at global level. The market due to several ongoing processes and certain achievements of the past is expected to continue to observe strong growth, with a CAGR rate of double-digit. There are numerous parameters that are associated with the market and acting as drivers. Some of the driving forces for the market are: increase in cancer cases, increase in cancer mortality rate, increase in awareness about the applications of cancer biological toxins and high failure rate of other therapies available in the market.

The unexpected status of the cancer biological toxin market has also resulted in challenging the business model of other therapies. The market's growing research spending amount and involvement of leading players of the pharmaceutical industry are also causing a robust demonstration of the applications and wide healthcare opportunities associated with the market. In addition, the therapy market is being measured as a superior therapy carrying all parameters for getting classified as a standard of care rather than just a usual cancer therapy for the patients. The healthy outcomes associated with the market are also directly linking the market to hedge over the highly expensive market such as chemotherapy, immunotherapy or any other combination therapy.

Table of Contents

1. Introduction to Biological Toxins

  • 1.1 Overview
  • 1.2 Evolution of Biological Toxins as Potent Anticancer Therapeutics

2. Role of Biological Toxins in Cancer Management

3. Types of Biological Toxins for Targeting Cancer

  • 3.1 Single Chain Biological Toxins
  • 3.2 Pore Forming Toxins
  • 3.3 Anthrax Toxins

4. Impact of Growing Cancer Biological Toxin Market on Other Viable Cancer Therapies

  • 4.1 Global Impact of Cancer Biological Toxin Therapy Market on Cancer Immunotherapy Market
    • 4.1.1 Cancer Biological Toxin Therapy Vs. Immune Checkpoint Inhibitor Therapy
    • 4.1.2 Cancer Biological Toxin Therapy Vs. Immunotherapy Monoclonal Antibodies
    • 4.1.3 Cancer Biological Toxins Therapy Market Vs. Cancer Vaccine Market
  • 4.2 Global Impact of Cancer Biological Toxin Therapy Market on Old & Traditional Cancer Therapies
    • 4.2.1 Cancer Biological Toxin Therapy Market Vs. Chemotherapy for Cancer Patients
    • 4.2.2 Cancer Biological Toxin Therapy Market Vs. Radiation Therapy for Cancer Treatment
    • 4.2.3 Cancer Biological Toxin Therapy Vs. Surgical Procedure for Cancer Treatment

5. Biological Toxins for Brain Tumors

  • 5.1 Toxins Used for Targeting Brain Tumors
  • 5.2 Pseudomonas Exotoxin-Based Immunotoxins for Brain Tumors
    • 5.2.1 IL4-PE
    • 5.2.2 IL13-PE
    • 5.2.3 TP-38
  • 5.3 Diphtheria Toxin-Based Immunotoxins for Brain Tumor
    • 5.3.1 Tf-CRM107
    • 5.3.2 DTAT & DTAT13
  • 5.4 Antigens for Targeting Brain Tumor
    • 5.4.1 Transferrin Receptor
    • 5.4.2 Interleukin-4 Receptor
    • 5.4.3 Interleukin-13 Receptor
    • 5.4.4 Epidermal Growth Factor Receptor
    • 5.4.5 Other Antigens

6. Biological Toxins Against Hematological Tumors

  • 6.1 Role of Biological Toxins in Leukemia & Lymphoma
  • 6.2 Ongoing Research & Development

7. Biological Toxins For Targeting Solid Tumors

  • 7.1 Impact on Solid Tumor Treatment
  • 7.2 Ongoing Research & Advancements

8. Biological Toxins for Breast Cancer

  • 8.1 Application of Biological Toxins in Breast Cancer
  • 8.2 Ongoing Development

9. Biological Toxins for Lung Cancer

  • 9.1 Role & Applications
  • 9.2 Recent Research & Development

10. Biological Toxins For Other Cancers

  • 10.1 Prostate Cancer
  • 10.2 Melanoma
  • 10.3 Colorectal Cancer
  • 10.4 Gynecological Cancer
  • 10.5 Gastrointestinal Cancers

11. Global Immunotoxin Market - Availability, Dosage, Patent & Price Analysis

  • 11.1 Lumoxiti (Moxetumomab pasudotox)

12. Research & Medical Advancement for Cancer Biological Toxin Market

  • 12.1 UCLA Researchers to Minimize Cancer Side Effects by Using Protein Derived from Diazona angulata
  • 12.2 Botulinum Toxin Effective against Stomach Cancer Cells in the Patients
  • 12.3 Botulinum Toxin A to Drastically Reduce Complications After Esophageal Cancer Treatment
  • 12.4 Botulinum Toxin A against Cutaneous Leiomyomas Indicating for Better Results
  • 12.5 TR1801-ADC Characterization for the Treatment of Advanced Solid Cancer
  • 12.6 Botulinum Toxin to Increase the Effectiveness of Chemotherapy & Radiation Therapy
  • 12.7 Botulinum Toxin A Cure for Persistent Pain after Breast Cancer Surgery
  • 12.8 Newly Discovered Botulinum Toxin X to have Potential for Treating Cancer & Other Diseases

13. Cancer Biological Toxins - Clinical Trial Insight

  • 13.1 By Phase
  • 13.2 By Status
  • 13.3 By Cancer Type
  • 13.4 By Countries

14. Global Cancer Biological Toxins Clinical Pipeline By Company, Indication & Phase

  • 14.1 Research
  • 14.2 Preclinical
  • 14.3 Phase-I
  • 14.4 Phase-I/II
  • 14.5 Phase-II
  • 14.6 Phase-II/III
  • 14.7 Phase-III
  • 14.8 Preregistration
  • 14.9 Registered

15. Marketed Cancer Biological Toxin Clinical Insight: Moxetumomab Pasudotox (Lumoxiti)

16. Global Cancer Biological Toxin Therapeutics Market Dynamics

  • 16.1 Favourable Market Parameters
  • 16.2 Market Challenges

17. Future Directions for Cancer Biological Toxin Market

18. Competitive Landscape

  • 18.1 Angimmune
  • 18.2 Eisai
  • 18.3 Molecular Template (mTEM)
  • 18.4 Astrazeneca
  • 18.5 Research Corporation Technologies
  • 18.6 Sanofi
  • 18.7 Seattle Genetics
  • 18.8 Roche
  • 18.9 Neopharma
  • 18.10 Xenova Biomedix

List of Figures

  • Figure 1-1: Evolution of Biological Toxins as Anticancer Therapeutics
  • Figure 2-1: Management of Biological Toxins in Cancer Treatment
  • Figure 3-1: Components of Immunotoxins
  • Figure 3-2: Components of Targeted Toxins
  • Figure 3-3: Types of Cancer Targeting Biological Toxins
  • Figure 3-4: Structure of Diphtheria Toxin & Denileukin diftitox (Ontak)
  • Figure 3-5: Mechanism of Denileukin diftitox (Ontak)
  • Figure 3-6: Mechanism of Pore Forming Biological Toxins
  • Figure 4-1: Cancer Biological Toxins Vs. Monoclonal Antibody
  • Figure 4-2: Old & Traditional Cancer Therapies Available in Therapeutics Market
  • Figure 4-3: Cancer Biological Toxin Therapy Action Vs. Chemotherapy Drug Action
  • Figure 4-4: Cancer Biological Toxin Vs. Surgical Removal of Cancer Cells
  • Figure 5-1: Commonly used Biological Toxins for Targeting Brain Tumor
  • Figure 5-2: Pseudomonas Exotoxin Based Immunotoxins
  • Figure 5-3: Diphtheria Toxin Based Immunotoxins under Development Phase
  • Figure 5-4: Antigens/ Receptors for Targeting Brain Tumor
  • Figure 5-5: Cintredekin Besudotox - Orphan Drug Designation Year by Indication
  • Figure 5-6: D2C7-IT Trial - Trial Initiation & Expected Completion Year
  • Figure 5-7: Role of Urokinase-Type Plasminogen Activator Receptor in Brain Tumor
  • Figure 6-1: Global - Newly Diagnosed Cases by Leading Types of Blood Cancer, 2020
  • Figure 6-2: Global - Newly Diagnosed Cases by Leading Types of Blood Cancer, 2020
  • Figure 6-3: Commonly used Biological Toxins for Targeting Haematological Tumor
  • Figure 6-4: Target Receptor for Ontak
  • Figure 6-5: Resimmune - FDA Orphan Designation & Fast Track Designation Year
  • Figure 6-6: Immunotoxin Receptors for Haematological Cancer
  • Figure 6-7: Investigational Immunotoxins for Haematological Cancer
  • Figure 6-8: Mechanism of LMB2 against Cells of Hematological Tumors
  • Figure 6-9: LMB-2 Phase II Trial - Study Initiation & Expected Completion Year
  • Figure 6-10: LMB-2 Phase I/II Trial - Study Initiation & Expected Completion Year
  • Figure 6-11: BL22 (CAT-3888) - Mechanism of Action against Hematological Malignancy
  • Figure 6-12: DT388GMCSF: Mechanism of Action Against Leukemia Cells
  • Figure 6-13: Resimmune - Mechanism of Action Against Cutaneous T Cell Lymphoma
  • Figure 6-14: Mechanism of MT-3724 in Hematological Cancer
  • Figure 6-15: MT-3724 Phase I/II Trial - Study Initiation & Expected Completion Year
  • Figure 6-16: MT-3724 Phase II Trial - Study Initiation & Expected Completion Year
  • Figure 7-1: Biological Toxins for Targeting Solid Tumors
  • Figure 7-2: Limitations of Immunotoxins in Solid Tumors
  • Figure 7-3: Immunotoxin for Solid Tumors by Target Receptor
  • Figure 7-4: Investigational Immunotoxins for Solid Tumor
  • Figure 7-5: SS1P - Mechanism of Action against Solid Tumor
  • Figure 7-6: LMB-100 - Mechanism of Action against Solid Tumors
  • Figure 7-7: LMB-100 Phase I Trial - Study Initiation & Expected Completion Year
  • Figure 7-8: LMB-100 Phase I/II Trial - Study Initiation & Expected Completion Year
  • Figure 7-9: LMB-7 - Mechanism of Action against Solid Tumors
  • Figure 8-1: Global - Newly Diagnosed Cases & Deaths related to Breast Cancer (Million), 2020
  • Figure 8-2: Biological Toxins Used for Targeting Breast Cancer
  • Figure 8-3: Approaches Used to Overcome Immunogenicity
  • Figure 8-4: Investigational Immunotoxins for Breast Cancer
  • Figure 9-1: Global - Newly Diagnosed Cases & Deaths related to Lung Cancer (Million), 2020
  • Figure 9-2: Biological Toxins used for Targeting Lung Cancer
  • Figure 9-3: Antigens/Receptors Expressed Over Lung Cancer Cells
  • Figure 9-4: Investigational Immunotoxins for Lung Cancer
  • Figure 10-1: Global - Newly Diagnosed Cases & Deaths related to Prostate Cancer (Million), 2020
  • Figure 10-2: Commonly used Biological Toxins for Targeting Prostate Cancer
  • Figure 10-3: Role of A-dmDT390-ScfbDb(PSMA) in Prostate Cancer
  • Figure 10-4: Investigational Immunotoxins for Prostate Cancer
  • Figure 10-5: Global - Newly Diagnosed Cases & Deaths related to Melanoma, 2020
  • Figure 10-6: Mechanism of PE Based Immunotoxins against Melanoma Cells
  • Figure 10-7: Antigens/Receptors Expressed Over Melanoma Cells
  • Figure 10-8: Mechanism of 9.2.27PE
  • Figure 10-9: Global - Newly Diagnosed Cases & Deaths related to Colon Cancer (Million), 2020
  • Figure 10-10: Global - Newly Diagnosed Cases & Deaths related to Rectum Cancer (Million), 2020
  • Figure 10-11: Antigens/Receptors Expressed Over Cells of Colorectal Cancer
  • Figure 10-12: Investigational Immunotoxins for Colorectal Cancer
  • Figure 10-13: BM7PE Trial - Study Initiation & Expected Completion Year
  • Figure 10-14: Global - Number of Newly Diagnosed Cases of Leading Gynecological Cancer, 2020
  • Figure 10-15: Global - Number of Deaths by Leading Gynecological Cancer, 2020
  • Figure 10-16: Antigens/Receptors Expressed Over Cells of Gynecological Cancers
  • Figure 10-17: Investigational Immunotoxins for Gynecological Cancer
  • Figure 10-18: Global - Number of Newly Diagnosed Cases of Leading Gastrointestinal Cancer, 2020
  • Figure 10-19: Global - Number of Deaths by Leading Gastrointestinal Cancer, 2020
  • Figure 10-20: Antigens/Receptors Expressed Over Cells of Gastrointestinal Cancers
  • Figure 10-21: Investigational Immunotoxins for Gastrointestinal Cancer
  • Figure 10-22: LMB-100 Phase Ib/II Trial - Study Initiation & Expected Completion Year
  • Figure 10-23: LMB-100 Phase I Trial - Study Initiation & Expected Completion Year
  • Figure 11-1: Lumoxiti - Year of Orphan Designation, FDA Approval & Patent Expiration
  • Figure 11-2: Lumoxiti - Duration of Single Treatment Cycle & Full Treatment (Weeks), January'2021
  • Figure 11-3: Lumoxiti - Number of Dose Required in Single Treatment Cycle & Full Treatment, January'2021
  • Figure 11-4: Lumoxiti - Cost of Single Dose, Single Treatment Cycle & Full Treatment of Hairy Cell Leukemia (US$), January'2021
  • Figure 13-1: Global - Number of Cancer Biological Toxins Related Clinical Trials by Phase, January'2021
  • Figure 13-2: Global - Cancer Biological Toxins Related Clinical Trials by Phase (%), January'2021
  • Figure 13-3: Global - Number of Cancer Biological Toxins Related Clinical Trials by Status, January'2021
  • Figure 13-4: Global - Cancer Biological Toxins Related Clinical Trials by Status (%), January'2021
  • Figure 13-5: Global - Number of Cancer Biological Toxins Related Clinical Trials by Indication, January'2021
  • Figure 13-6: Global - Cancer Biological Toxins Related Clinical Trials by Indication (%), January'2021
  • Figure 13-7: Global - Number of Cancer Biological Toxins Related Clinical Trials by Region, January'2021
  • Figure 13-8: Global - Number of Cancer Biological Toxins Related Phase I Clinical Trials by Region, January'2021
  • Figure 13-9: Global - Number of Cancer Biological Toxins Related Phase I-II Clinical Trials by Region, January'2021
  • Figure 13-10: Global - Number of Cancer Biological Toxins Related Phase I-II Clinical Trials by Region, January'2021
  • Figure 16-1: Drivers for the Growth of Cancer Biological Toxin Market
  • Figure 17-1: Global - Cancer Biological Toxins Expected Market Opportunity (US$ Million), 2021 -2026
  • Figure 17-2: Parameters Driving the Future Insight for Cancer Biological Toxin Market